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Recently, it was shown that interferon-g mediated immune responses, which play a major role in the
control of infection with Mycobacterium tuberculosis (Mtb), can be inhibited by type I interferons. Since
type I interferons are abundantly induced during viral infections, we hypothesized that infections with
inﬂuenza viruses might play a role in the development of active TB disease either directly after exposure
to Mtb or through reactivation of latent Mtb infection. To explore this hypothesis we investigated in a
retrospective study whether newly diagnosed adult tuberculosis patients from Indonesia had had recent
inﬂuenza infection. Plasma samples from TB patients and controls were assayed for antibodies against
two subtypes of at that time relevant, seasonal inﬂuenza A viruses. Overall, no correlation was observed
with the presence of antibodies and manifest tuberculosis. Still, antibody titers against circulating
A/H3N2 inﬂuenza virus were slightly enhanced in tuberculosis patients as compared to controls, and
highest in cases of advanced tuberculosis. This suggests that tuberculosis patients were recently infected
with inﬂuenza, before clinical manifestation of the disease. Alternatively, the production of antibodies
and susceptibility to tuberculosis may be inﬂuenced by a common confounding factor, for example the
ability of patients to induce interferon-a. We conclude that in an endemic country like Indonesia, an
inﬂuenza virus infection is not a major determinant for developing clinically manifest tuberculosis.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Tuberculosis (TB) is a severe disease caused by Mycobacterium
tuberculosis (Mtb). Up to 10% of the Mtb infected individuals
develop active tuberculosis, while the majority of those infected
develop a latent state of infection for years.1,2 During latency, Mtb
may stay quiescent, but when the immune system fails to control
the bacteria, reactivationmay occur and precipitate development of
active disease,3,4 in most cases pulmonary TB disease.
Several risk factors that inﬂuence the susceptibility to TB have
been described, such as host genetic factors,5 malnutrition,6
smoking,7 diabetes8 and infection with HIV.9 Besides these factors
also the Mtb strain virulence may inﬂuence the course of TB, since
virulent Mtb can inhibit the host immune system in various ways.10: þ31 71 526 6758.
e Vosse).
evier OA license.Recently, IFN-a has been described as a putative factor, which may
be induced by highly virulent Mtb strains11,12 and can inhibit an
effective IFN-g mediated immune response.13e15 Mouse studies
revealed that during Mtb infection IFN-a is induced and that IFN-g
mediated immune responses can be impaired by IFN-a.12,16 In
humans, a typical IFN-a/b transcript signature was found in the
blood cells from TB patients.11,17,18 However, it is not clear whether
Mtb infection in humans leads to the production of type I in-
terferons or whether production of type I interferons leads to TB. It
is possible that in TB patients type I interferons are more abun-
dantly induced due to infections with viruses, such as pneumo-
tropic inﬂuenza viruses.
After inﬂuenza virus infection a period of enhanced suscepti-
bility to bacterial infections is commonly seen in humans.19 In mice,
Toll like receptor-induced responses of alveolar macrophages to
bacterial ligands remain desensitized for months after an inﬂuenza
virus infection.20 This explains why mice are highly susceptible
to bacterial pneumonia for several weeks after inﬂuenza virus
R.A. de Paus et al. / Tuberculosis 93 (2013) 338e342 339infection.21 In humans, post-inﬂuenza bacterial pneumonia is a
major cause of morbidity,19 with Streptococcus pneumonia as the
main pathogen associated with post-inﬂuenza pneumonia.22 TB is
usually not diagnosed shortly after inﬂuenza infections and
although some anecdotal reports suggest that the occurrence of TB
was also high during inﬂuenza pandemics,23e25 a causal relation-
ship between the epidemics of the two infectious diseases has not
been investigated.
If indeed an inﬂuenza virus infection leads to the (re)-activation
of a latent Mtb infection, this may remain unnoticed, because the
period between (re)-activation of the bacteria and the ﬁrst pre-
sentation of the clinical symptoms of TB is long. TB develops slowly,
due to the slowmetabolism and replication rate of Mtb. Thus it may
be that within the latency period of TB, during the primary infec-
tion or after re-infection, a transient inhibitory effect on the anti-
bacterial responses by an inﬂuenza virus infection inﬂuences the
course of TB and leads to active disease, possibly in conjunction
with other risk factors. In mice, co-infections of inﬂuenza viruses
with Mtb enhanced the development of TB in the lungs.26 In
humans, it is still unclear whether inﬂuenza virus infections can
inﬂuence the course of TB.
We hypothesized that inﬂuenza virus infections may promote
the development of active disease after exposure to Mtb, or
might play a role in the reactivation of latent Mtb infection. To
explore this hypothesis we investigated in a retrospective study
whether patients with clinically-manifest TB had an inﬂuenza
virus infection recently. Plasma samples collected from TB pa-
tients at time of diagnosis and from controls were screened for
the presence of antibodies against inﬂuenza viruses in order to
investigate a putative association between TB and inﬂuenza virus
infections.2. Patients, materials and methods
2.1. Study subjects
Patients and controls (Table 1) were recruited between March
2001 and December 2004 from the TB clinic “Perkumpulan Pem-
berantasan Tuberkulosis Indonesia” in Jakarta.8,27,28 Patients newly
diagnosed with active pulmonary TB, between the age of 15 and 70,
were included. TB diagnosis was based on WHO deﬁnitions
including the presence of clinical symptoms, a chest X-ray exami-
nation (CXR), microscopic detection of acid-fast bacilli in sputum
and a positive culture of Mtb. Based on the CXR examinations TB
patients were classiﬁed into two groups; patients with mild to
moderate TB and patients with advanced TB. Patients seropositive
for HIV were excluded. Community control subjects were recruited
from neighboring houses and matched for age, sex and socio-
economic class. Controls with a history of TB or with positive TB
ﬁnding in the CXR were excluded. The control subjects underwent
the same examinations as the patients, but were not tested for HIV,
since the prevalence of HIV in the Indonesian population was low,
as evidenced by the low prevalence of HIV amongst the TB patientsTable 1
Description of the study population.
TB patients
(n ¼ 111)
Controls
(n ¼ 111)
p-Value
Age in years (median) 18e6731 17e6935 0.153*
Gender; males 72 (65%) 60 (54%) 0.132y
Diabetes mellitus 24 (22%) 8 (8%) <0.001y
Individuals with BCG scar 39 (35%) 45 (41%) 0.489y
* Student t-test.
y c2 test.in this cohort (1.8%).29 The inﬂuenza vaccination status of our study
cohort is unknown. However, at the time of our study, vaccination
against inﬂuenza viruses in Indonesia was only rarely applied and
based on the low socio-economic status of our patients and
matched controls these individuals are extremely unlikely to have
received such vaccinations. For this study, the patients and controls
were matched for the date of inclusion. Patients and matched
controls were only included if the dates of inclusion were not more
than 14 days apart. Written informed consent was obtained from all
subjects. The study was approved by the Ethical Committee of the
Medical Faculty, University of Indonesia.
2.2. Detection of antibodies against inﬂuenza viruses
Heparinized plasma samples were obtained from the patients
and controls and stored at 80 C. Thawed plasmas were analyzed
for the presence of total IgG and IgM antibodies against two sub-
types of inﬂuenza A virus, a H3N2 virus (A/Moscow/10/99, vaccine
strain ResVir-17) and a H1N1 virus (A/New Caledonia/20/99, vac-
cine strain IVR-116), using the hemagglutinating inhibition (HI)
test. These strains were chosen because of their high antigenic
similarity to the speciﬁc H3N2 and H1N1 viruses circulating during
the sample period. For use in the HI test, the inﬂuenza virus strains
were propagated in 11-day old embryonated chicken eggs. The HI
test was performed in duplicate according to standard methods30
with turkey erythrocytes and four hemagglutinating units of
virus. Ferret sera raised against the test antigens were used as
positive controls. All plasma samples of all study subjects were
tested simultaneously, in duplicate, and were only regarded posi-
tive when both analyses gave positive results. The threshold of
detection was an HI titer 10.
2.3. Statistical analysis
Data were analyzed using SPSS software. The Pearson c2 test
and the paired samples t-test were regarded signiﬁcant when
p < 0.05.
3. Results
3.1. No correlation between the incidence of tuberculosis and the
seroprevalence of antibodies against inﬂuenza viruses
To study the effect of inﬂuenza virus infections on TB we
examined the plasma samples of controls and newly identiﬁed TB
patients for the presence or absence of antibodies against two
subtypes of inﬂuenza A virus, H1N1 and H3N2 (Table 2). The
threshold of detection was an HI titer 10. Both inﬂuenza strains
circulated in the population during the time of plasma sampling:
46% of the TB patients and 41% of the controls had antibodies
against H1N1, while 82% of the TB patients and 82% of the controls
had antibodies against H3N2 (Table 2). No signiﬁcant differences in
the number of individuals with antibodies against inﬂuenza viruses
were thus observed between the control group and the group of TB
cases.Table 2
Seroprevalence of antibodies to A/H1N1 and A/H3N2 inﬂuenza viruses.
Group H1N1 positive H3N2 positive
TB patients (n ¼ 111) 51 (46%) 91 (82%)
Controls (n ¼ 111) 46 (41%) 91 (82%)
Total (n ¼ 222) 97 (44%) 182 (82%)
c2 test; p-value p ¼ 0.499 p ¼ 1.000
The threshold of detection was an HI titer of 10.
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manifestation of tuberculosis
Because yearly inﬂuenza infection rates are estimated to be 5e
10%31 the high percentage of individuals with H1N1 and H3N2
antibodies indicate that many of these individuals were already
exposed to these viruses in the past. Therefore, the magnitude of
the antibody responses might be a better indication of recent
exposure as IgG antibody levels will be boosted upon reinfection
and will only wane partially. Hence, we examined the titers of
antibodies against H1N1 and H3N2 inﬂuenza viruses in the TB and
control group. The results are displayed in Table 3 and Figure 1. The
geometric means of the titers of antibodies against the H3N2 and
the H1N1 inﬂuenza viruses were higher (respectively 1.7 and 1.4
times) for the total group of pulmonary TB patients, as compared to
the titers of the control group. Statistical analysis using the paired
sample t test showed that only for the titers of antibodies against
H3N2 this difference was signiﬁcant. We next determined whether
there is a correlation between the severity of the disease and the
antibody titers against H3N2. The cases of advanced pulmonary TB
showed a higher geometric mean titer for H3N2 (1.8 times), while
the group of cases with mild and moderate TB showed a smaller
increase (1.4 times) in the geometric mean titer, as compared to the
matched controls. The difference in these titers was signiﬁcant
between the cases with advanced TB and their matched controls
but not between the cases of mild to moderate TB and their
matched controls. The geometric mean titer of antibodies against
H3N2 inﬂuenza viruses for the extrapulmonary TB patients was
even higher (2.0 times as compared to the matched controls).
However, the latter patient group was small (n ¼ 10) and the
antibody titers of the cases with extrapulmonary TB were not
signiﬁcantly different from the titers of their matched controls.
3.3. The inﬂuence of diabetes mellitus on tuberculosis and the titers
of antibodies to inﬂuenza viruses
In a previous study from our group, with the large cohort of
patients and controls from Indonesia, Diabetes mellitus (DM) was
identiﬁed as a risk factor for TB.8 Since having DM is correlatedwith
the incidence of TB in this study (Table 1) we investigated whether
having DM could be a factor of inﬂuence on inﬂuenza virus speciﬁc
antibody levels. Hence, we compared the inﬂuenza virus speciﬁc
antibody titers between the TB cases and their matched controls,
while excluding individuals with DM from both groups.
The group of patients with pulmonary TB and without DM
showed still signiﬁcantly higher amounts of antibodies againstTable 3
Number of positive cases and mean antibody titers against A/H3N2 and A/H1N1
inﬂuenza viruses for the different groups of TB patients and their matched controls.
H3N2 H1N1
n Mean* p-Valuey n Mean* p-Valuey
Total TB patients 72 244 0.002 25 72 0.330
Matched controls 72 145 25 51
Mild and moderate TB 33 211 0.152 11 52 0.995
Matched controls 33 147 11 52
Advanced TB 33 262 0.021 14 93 0.222
Matched controls 33 142 14 50
Only pulmonary TB 62 234 0.004 21 69 0.267
Matched controls 62 143 21 45
Extrapulmonary TB 10 319 0.289 4 92 0.986
Matched controls 10 157 4 94
TB patients without DM 55 271 0.030 20 70 0.496
Matched controls
without DM
55 148 20 54
* Geometric mean.
y Paired student t-test.H3N2 as compared to their matched controls, (paired sample t test,
Table 3 and Figure 1F). Themean titer of antibodies against H3N2 of
the TB cases with DM was on the other hand signiﬁcantly lower
(student t test, p¼ 0.049) as comparedwith themean titer of the TB
cases without DM (data not shown).
4. Discussion
The main ﬁnding of this report is that there is no correlation
between the seroprevalence of antibodies against inﬂuenza A
viruses and the development of clinically active TB in an Indonesian
cohort. However, we observed an association between the level of
antibody titers against inﬂuenza A/H3N2 virus and the stage of
active TB lung disease. Compared to the control group the mean
antibody titer of the group of TB patients was slightly enhanced,
which may indicate that the TB patients were recently re-infected
with an inﬂuenza virus strain, suggesting that an inﬂuenza virus
infection precedes and inﬂuences the clinical manifestation of TB.
However, such an epidemiological association may not be causal,
and be confounded.
Previously, it was suggested that an association existed between
the 20th century inﬂuenza pandemics and the incidence of TB.23e25
The existence of this correlation can however be questioned
because diagnoses in the early 20th century were based solely on
clinical symptoms. In addition, an increased incidence of both
diseases may also be explained by common susceptibility factors,
such as malnutrition. Here, we tested the hypothesis that inﬂuenza
virus infections enhance the susceptibility to develop active TB.
Although we did not ﬁnd an association between the number of
people with antibodies against inﬂuenza viruses and the develop-
ment of TB, the difference in inﬂuenza A/H3N2 virus speciﬁc anti-
body titers between TB cases and controls may suggest that more
TB cases than controls were recently re-infected, or have been
exposed more often, with these seasonal inﬂuenza viruses. A
drawback of our study is the high (pre-existing) seroprevalence of
the antibodies against H3N2. Detection of antibodies against spe-
ciﬁc epitopes of the most recent inﬂuenza subtypes was unfortu-
nately not possible, due to the low antigenic drift between the
latest seasonal inﬂuenza viruses.
Within the group of TB patients the cases with extrapulmonary
manifestation of the disease showed the highest mean antibody ti-
ters against A/H3N2 viruses. This association suggests that the clin-
icalmanifestation of extrapulmonary infections occurs inTB patients
with stronger antibody responses after inﬂuenza virus infections.
Dissemination of mycobacterial infections are more common in
hosts with impaired immunity, for example in MSMD patients with
impaired IFN-gmediated immune responses32 or in HIV patients.33
In patients with extrapulmonary TB the plasma concentrations of
IFN-g are also reduced, as compared to patients with pulmonary
TB.34 Therefore, we speculated that viruses other than HIV, like
inﬂuenza viruses, affect the Th1 immunity against mycobacteria and
in this way inﬂuence the course of TB. In mice it was indeed found
that inﬂuenza virus infection aggravates the course of TB.26 It is un-
clear whether this is also the case in humans. Our cohort was too
small to assess whether the risk of extrapulmonary manifestation is
increased due to inﬂuenza virus infections.
The ﬁnding that TB patients had slightly higher plasma antibody
levels to A/H3N2 inﬂuenza virus than the control group suggests a
relation exists between inﬂuenza virus infections and the clinical
manifestation of tuberculosis. However, the association may very
well be confounded. One possible confounding factor is that a co-
infection with an inﬂuenza virus in patients with TB may be more
severe or lasts longer due to lung damage by Mtb, and as a result
more antibodies against the virus are generated. Another possible
confounding factor is that Mtb infection may result in the
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Figure 1. Antibody titer against A/H3N2 in the different groups from the Indonesian TB cohort. The antibody titers against A/H3N2 were determined for the groups of TB cases and
their matched controls. The data of the TB cases and the paired controls, matched for the date of inclusion, that were both found positive for the presence of antibodies are
displayed. The group of total TB cases (A) was divided into a group with mild to moderate pulmonary TB (B) and a group of cases with advanced pulmonary (C) according to CXR
examinations. In a separate analysis the group of total TB cases was divided in a group of cases with only pulmonary TB (D) and a group of cases with signs of extrapulmonary TB (E).
In addition, the TB cases without diabetes mellitus (DM) were compared with their matched controls without DM (F). The geometric mean of the antibody titers is indicated with a
line. Cases were compared with their matched controls and statistical analysis was performed on logarithmic values of the antibody titers using the t-test for matched pairs.
R.A. de Paus et al. / Tuberculosis 93 (2013) 338e342 341polyclonal activation of B cells, as was observed in mice after
infection with various microorganisms.35 Human memory B cells
were also found, in response to a strong stimulus, to polyclonally
produce small amounts of antibodies in the absence of speciﬁc
antigens.36 Whether such non-speciﬁc antibody production also
occurs during Mtb infection and results in a detectable rise in anti-
inﬂuenza antibodies is yet unknown. Since plasma of TB patients
before the manifestation of the disease is unavailable we were
unable to determine whether the anti-inﬂuenza antibodies rise
upon development of TB. The ability to produce high amounts of
IFN-a may also be a confounding factor. Some individuals are
relatively strong producers of type I interferons37 and because of
this they may produce both higher amounts of antibodies against
viral pathogens and may be more susceptible to developing TB.In addition, TB may be aggravated if Mtb induced type I interferons
are also more abundant in these individuals, as they may impair an
effective IFN-g mediated immune response.11 Another potential
confounding factor may be diabetes mellitus (DM) since DM was
previously found to be a risk factor for developing TB.8 We inves-
tigated whether DM cases had higher antibody titers against the
viruses. Based on our results, we could exclude DM as a con-
founding factor.
Our ﬁndings are based on a retrospective study with TB cases in
Jakarta (Indonesia) in the period from March 2001 till December
2004. This is the ﬁrst study which investigates a potential role for
viral infections in the development of TB by determining the
presence of antibodies against inﬂuenza viruses in plasmas of TB
patients and matched controls. In order to determine whether the
R.A. de Paus et al. / Tuberculosis 93 (2013) 338e342342observed association between TB and higher virus-speciﬁc anti-
body titers indeed indicates an increased risk for TB after inﬂuenza
virus infection and to exclude that confounding factors cause the
increase in the antibody response to inﬂuenza viruses, a prospec-
tive study is needed. Although such a study would be difﬁcult to set
up, this should preferably investigate the inﬂuence of primary viral
infections on the manifestation of TB in childhood. In such a cohort
it would be possible to prove new, primary inﬂuenza virus
infections.
A prospective study for adult TB is also possible, but because
many adults already have antibodies against previous seasonal vi-
ruses (that may cross-react with contemporary viruses) novel
infections will have to be identiﬁed by demonstrating antibody
titers rises against a new seasonal strain. The current study was
cross sectional and identiﬁed a high seroprevalence of antibodies
against two subtypes (44% and 82% for H1N1 and H3N2 respec-
tively) indicating that a large proportion of study subjects were
infected during previous epidemics, as normally about 5e10% of the
population are affected during annual inﬂuenza epidemics.31
Studies of larger cohorts and screening for strain-speciﬁc anti-
bodies may provide more insights into the effects of co-infections
with inﬂuenza viruses on the occurrence and severity of TB.
Based on our results we conclude that inﬂuenza virus infections
are not a major determinant in the development of clinically active
TB in adults, either through reactivation of latent disease or directly
after exposure to the bacillus, nor of more severe manifestation of
the disease. The identiﬁed correlation between the titers of anti-
bodies against inﬂuenza viruses and the manifestation of TB, is still
in line with the suggestion that type I interferons may play a role in
the immunopathogenesis of TB.
Ethical approval: The study was approved by the ethical
committee of the Medical Faculty, University of Indonesia.
Funding: This study was supported partly by a grant from the
Royal Netherlands Academy of Arts and Sciences
(KNAW99MED01) and received supplementary support from
NWO-PRIOR. The research also received funding from the Euro-
pean Union’s Seventh Framework Programme (FP7/2007e2013)
for projects NEWTBVAC; IDEA; and ADITEC (No: 280873).
Competing interest: The authors have no conﬂict of interest.
References
1. World Health Organization: WHO report 2009. Global tuberculosis control -
epidemiology, strategy, ﬁnancing, who int/tb/publications/global_report/2009/
en/index html; 2009.
2. Ottenhoff THM, Kaufmann SHE. Vaccines against tuberculosis: where are we
and where do we need to go? PloS Pathog 2012;85:e1002607.
3. Ehlers S. Lazy, dynamic or minimally recrudescent? On the elusive nature and
location of the mycobacterium responsible for latent tuberculosis. Infection
2009;37:87e95.
4. Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection.
Infection 2009;37:80e6.
5. Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E. Control of human host
immunity to mycobacteria. Tuberculosis (Edinb) 2005;85:53e64.
6. Cegielski JP, McMurray DN. The relationship between malnutrition and
tuberculosis: evidence from studies in humans and experimental animals. Int J
Tuberc Lung Dis 2004;8:286e98.
7. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis
from exposure to tobacco smoke: a systematic review and meta-analysis. Arch
Intern Med 2007;167:335e42.
8. Alisjahbana B, van Crevel R, Sahiratmadja E, den Heijer M, Maya A, Istriana E,
et al. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int
J Tuberc Lung Dis 2006;10:696e700.
9. Aaron L, Saadoun D, Calatroni I, Launay O, Memain N, Vincent V, et al. Tuber-
culosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect
2004;10:388e98.
10. Ottenhoff THM. New pathways of protective and pathological host defense to
mycobacteria. Trends Microbiol 2012;20:419e28.11. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-
inducible neutrophil-driven blood transcriptional signature in human tuber-
culosis. Nature 2010;466:973e7.
12. Manca C, Tsenova L, Freeman S, Barczak AK, Tovey M, Murray PJ, et al.
Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and
increase expression of negative regulators of the Jak-Stat pathway. J Interferon
Cytokine Res 2005;25:694e701.
13. Nagai T, Devergne O, van Seventer GA, van Seventer JM. Interferon-b mediates
opposing effects on interferon-g-dependent Interleukin-12 p70 secretion by
human monocyte-derived dendritic cells. Scand J Immunol 2007;65:107e17.
14. de Paus RA, Van Wengen A, Schmidt I, Visser M, Verdegaal EME, van Dissel JT,
et al. Inhibition of the type I immune responses of human monocytes by IFN-a
and IFN-b. Cytokine 2013;61:645e55.
15. van de Wetering D, Van Wengen A, Savage ND, van de Vosse E, van Dissel JT.
IFN-a cannot substitute lack of IFN-g responsiveness in cells of an IFN-gR1
deﬁcient patient. Clin Immunol 2011;138:282e90.
16. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, et al. Viru-
lence of a Mycobacterium tuberculosis clinical isolate in mice is determined by
failure to induce Th1 type immunity and is associated with induction of IFN-a/
b. Proc Natl Acad Sci U S A 2001;98:5752e7.
17. Maertzdorf J, Weiner III J, Mollenkopf HJ, Bauer T, Prasse A, Muller-
Quernheim J, et al. Common patterns and disease-related signatures in
tuberculosis and sarcoidosis. Proc Natl Acad Sci USA 2012;109:7853e8.
18. Ottenhoff THM, Hari Dass R, Yang N, Zhang M, Wong HEE, Sahiratmadja E, et al.
Genome-wide expression proﬁling identiﬁes Type I interferon response
pathways in active tuberculosis. PlosOne 2012;7(9):e45839.
19. Ballinger MN, Standiford TJ. Postinﬂuenza bacterial pneumonia: host defenses
gone awry. J Interferon Cytokine Res 2010;30:643e52.
20. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebien M, et al. Sus-
tained desensitization to bacterial Toll-like receptor ligands after resolution of
respiratory inﬂuenza infection. J Exp Med 2008;205:323e9.
21. McCullers JA, Rehg JE. Lethal synergism between inﬂuenza virus and Strepto-
coccus pneumoniae: characterization of a mouse model and the role of platelet-
activating factor receptor. J Infect Dis 2002;186:341e50.
22. McNamee LA, Harmsen AG. Both inﬂuenza-induced neutrophil dysfunction
and neutrophil-independent mechanisms contribute to increased susceptibil-
ity to a secondary Streptococcus pneumoniae infection. Infect Immun 2006;74:
6707e21.
23. Housworth J, Langmuir AD. Excess mortality from epidemic inﬂuenza, 1957e
1966. Am J Epidemiol 1974;100:40e8.
24. Lofgren S, Callans A. Asian inﬂuenza and pulmonary tuberculosis. Acta Med
Scand 1959;164:523e7.
25. Noymer A. The 1918-19 inﬂuenza pandemic affected tuberculosis in the United
States: reconsidering Bradshaw, Smith, and Blanchard. Biodemography Soc Biol
2008;54:125e33.
26. Volkert M, Pierce C, Horsfall FL, Dubos RJ. The enhancing effect of concurrent
infection with pneumotropic viruses on pulmonary tuberculosis in mice. J Exp
Med 1947;86:203e14.
27. Sahiratmadja E, Alisjahbana B, Buccheri S, Di Liberto D, de Boer T, Adnan I, et al.
Plasma granulysin levels and cellular interferon-gamma production correlate
with curative host responses in tuberculosis, while plasma interferon-gamma
levels correlate with tuberculosis disease activity in adults. Tuberculosis
(Edinb) 2007;87:312e21.
28. Sahiratmadja E, Alisjahbana B, de Boer T, Adnan I, Maya A, Danusantoso H, et al.
Dynamic changes in pro- and anti-inﬂammatory cytokine proﬁles and gamma
interferon receptor signaling integrity correlate with tuberculosis disease
activity and response to curative treatment. Infect Immun 2007;75:820e9.
29. van Crevel R, Parwati I, Sahiratmadja E, Marzuki S, Ottenhoff TH, Netea MG,
et al. Infection with Mycobacterium tuberculosis Beijing genotype strains is
associated with polymorphisms in SLC11A1/NRAMP1 in Indonesian patients
with tuberculosis. J Infect Dis 2009;200:1671e4.
30. World Health Organization: Global Inﬂuenza Surveillance Network. Manual for
the laboratory diagnosis and virological surveillance of inﬂuenza 2011, who int/
inﬂuenza/resources/documents/manual_diagnosis_surveillance_inﬂuenza/en/
index html; 2011.
31. Inﬂuenza. World Health Organization, www who int/biologicals/vaccines/
inﬂuenza/en/; 2012.
32. van de Vosse E, Hoeve MA, Ottenhoff TH. Human genetics of intracellular in-
fectious diseases: molecular and cellular immunity against mycobacteria and
salmonellae. Lancet Infect Dis 2004;4:739e49.
33. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, et al. Identiﬁcation of
risk factors for extrapulmonary tuberculosis. Clin Infect Dis 2004;38:199e205.
34. Hasan Z, Jamil B, Khan J, Ali R, Khan MA, Nasir N, et al. Relationship between
circulating levels of IFN-g, IL-10, CXCL9 and CCL2 in pulmonary and extrap-
ulmonary tuberculosis is dependent on disease severity. Scand J Immunol
2009;69:259e67.
35. Montes CL, Acosta-Rodriguez EV, Merino MC, Bermejo DA, Gruppi A. Polyclonal
B cell activation in infections: infectious agents’ devilry or defense mechanism
of the host? J Leukoc Biol 2007;82:1027e32.
36. Lanzavecchia A, Bernasconi N, Traggiai E, Ruprecht CR, Corti D, Sallusto F.
Understanding and making use of human memory B cells. Immunol Rev
2006;211:303e9.
37. Katschinski DM, Neustock P, Kluter H, Kirchner H. Inﬂuence of various factors
on interferon-a production in cultures of human leukocytes. J Interferon Res
1994;14:105e10.
